Clinical Report: MR-Guided Focal Boost Radiotherapy for Prostate Cancer
Overview
MR-guided focal boost radiotherapy targeting intraprostatic lesions (IPLs) in localized prostate cancer improves biochemical disease-free survival (bDFS) without increasing toxicity. A systematic review of seven prospective trials including 723 patients supports this approach as a promising strategy to enhance tumor control while minimizing side effects.
Background
Standard radiation therapy for prostate cancer delivers a uniform dose to the entire prostate, which improves biochemical control but increases late toxicity risks. Local recurrence typically occurs at the dominant tumor site, motivating dose escalation specifically to these intraprostatic lesions (IPLs). Multiparametric MRI, standardized by PI-RADS, enables accurate identification and delineation of IPLs for targeted dose escalation. The FLAME trial and subsequent studies have demonstrated improved outcomes with MR-guided focal boosts without compromising quality of life.
Data Highlights
Study
Design
Patients (n)
Risk Groups
Median Follow-up (months)
bDFS (%)
Toxicity
FLAME Trial (Kerkmeijer et al.)
Randomized Phase III
571
Intermediate, High
~72
Improved with focal boost
No increase in late toxicity
Poon et al. Meta-analysis
Meta-analysis of 17 studies
Data pooled
Various
>60
92.4% (95% CI 84.5–97.7%)
Acceptable toxicity profile
Other Phase II Trials
Prospective Phase II
152
Low, Intermediate, High
36+
Consistent bDFS improvement
Low acute and late toxicity
Key Findings
MR-guided focal boost to IPLs significantly improves biochemical disease-free survival compared to uniform prostate irradiation.
The FLAME randomized phase III trial demonstrated improved bDFS without increased toxicity or reduced quality of life.
Meta-analysis of 17 prospective studies showed a pooled 5-year bDFS of 92.4% with focal boost treatment.
Focal boost strategies maintain acceptable acute and late toxicity profiles, reducing radiation exposure to normal tissues.
Multiparametric MRI with PI-RADS standardization is critical for accurate IPL identification and treatment planning.
Barriers to clinical implementation include imaging variability and treatment planning complexity, but ongoing trials and technological advances are addressing these challenges.
Clinical Implications
Incorporating MR-guided focal boost radiotherapy into treatment plans for localized prostate cancer can enhance tumor control while minimizing toxicity. Clinicians should consider multiparametric MRI for precise IPL delineation to optimize dose escalation. Adoption of this approach requires multidisciplinary coordination and familiarity with advanced imaging and radiation delivery techniques.
Conclusion
MR-guided focal boost radiotherapy represents a clinically effective and safe strategy to improve outcomes in localized prostate cancer by targeting dominant intraprostatic lesions. Continued research and implementation efforts are warranted to integrate this approach into standard practice.
References
Kerkmeijer et al. 2021 -- FLAME Trial: Focal Boost Radiotherapy in Prostate Cancer
Poon et al. 2021 -- Meta-analysis of MR-guided Focal Boost Radiotherapy
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.
